Information Provided By: 
Fly News Breaks for November 6, 2019
PRQR
Nov 6, 2019 | 15:07 EDT
JMP Securities analyst Liisa Bayko reiterated an Outperform rating and $25 price target on ProQR Therapeutics after the company reported Q3 results. The analyst noted that the company ended the quarter with ~$137M in pro forma cash, which management guided to as sufficient runway into 2022. Bayko sees the next major catalyst for ProQR being proof-of-concept data for QR-421a in Usher syndrome in Q1 of 2020, adding this this is "a significant opportunity... which we estimate could reach ~$1B."
News For PRQR From the Last 2 Days
PRQR
Apr 23, 2024 | 07:17 EDT
ProQR Therapeutics (PRQR) announced the Annual General Meeting, AGM, of Shareholders will take place on Wednesday, May 22, 2024 at the offices of Allen & Overy LLP, in Amsterdam, the Netherlands. As part of the AGM, Martin Maier, PhD, is nominated for appointment as a non-executive Board Member for a period of four years. Dr. Maier is Senior Vice President Research heading the Oncology group at Alnylam Pharmaceuticals (ALNY).
